References
- Folch J, Lees M, Sloane Stanley GH. (1957). A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226:497–509
- Forrester JS, Milne SB, Ivanova PT, Brown HA. (2004). Computational lipidomics: a multiplexed analysis of dynamic changes in membrane lipid composition during signal transduction. Mol Pharmacol 65:813–21
- Friedman AN, Yu Z, Denski C, et al. (2013). Fatty acids and other risk factors for sudden cardiac death in patients starting hemodialysis. Am J Nephrol 38:12–18
- Hla, T, Dannenberg AJ. (2012). Sphingolipid signaling in metabolic disorders. Cell Metab 16:420–34
- Jia L, Wang C, Kong H, et al. (2007a). Effect of PA-MSHA vaccine on plasma phospholipids metabolic profiling and the ratio of Th2/Th1 cells within immune organ of mouse IgA nephropathy. J Pharm Biomed Anal 43:646–54
- Jia L, Wang C, Zhao S, et al. (2007b). Metabolomic identification of potential phospholipid biomarkers for chronic glomerulonephritis by using high performance liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 860:134–40
- Lam, SM, Shui G. (2013). Lipidomics as a principal tool for advancing biomedical research. J Genet Genomics 40:375–90
- Lee S, Lee YS, Choi KM, et al. (2012). Quantitative analysis of sphingomyelin by high-performance liquid chromatography after enzymatic hydrolysis. Evid Based Complement Alternat Med 2012: Article ID 396218, 9 pages
- Lee YK, Lee DH, Kim JK, et al. (2013). Lysophosphatidylcholine, oxidized low-density lipoprotein and cardiovascular disease in Korean hemodialysis patients: analysis at 5 years of follow-up. J Korean Med Sci 28:268–73
- Li M, Feng B, Liang Y, et al. (2013). Lipid profiling of human plasma from peritoneal dialysis patients using an improved 2D (NP/RP) LC-QToF MS method. Anal Bioanal Chem 405:6629–38
- Liu R, Peng Y, Li X, et al. (2013). Identification of plasma metabolomic profiling for diagnosis of esophageal squamous-cell carcinoma using an UPLC/TOF/MS platform. Int J Mol Sci 14:8899–911
- Makinen VP, Tynkkynen T, Soininen P, et al. (2012). Sphingomyelin is associated with kidney disease in type 1 diabetes (The FinnDiane Study). Metabolomics 8:369–75
- Nicolson GL, Ash ME. (2014). Lipid Replacement Therapy: a natural medicine approach to replacing damaged lipids in cellular membranes and organelles and restoring function. Biochim Biophys Acta 1838:1657--79
- Niwa T. (2008). Biomarker discovery for kidney diseases by mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 870:148–53
- Obinata H, Hla T. (2012). Sphingosine 1-phosphate in coagulation and inflammation. Semin Immunopathol 34:73–91
- Oursel D, Loutelier-Bourhis C, Orange N, et al. (2007). Lipid composition of membranes of Escherichia coli by liquid chromatography/tandem mass spectrometry using negative electrospray ionization. Rapid Commun Mass Spectrom 21:1721–8
- Pavoine C, Pecker F. (2009). Sphingomyelinases: their regulation and roles in cardiovascular pathophysiology. Cardiovasc Res 82:175–83
- Pulfer M, Murphy RC. (2003). Electrospray mass spectrometry of phospholipids. Mass Spectrom Rev 22:332–64
- Stegemann C, Pechlaner R, Willeit P, et al. (2014). Lipidomics profiling and risk of cardiovascular disease in the prospective population-based bruneck study. Circulation 129:1821–31
- Van Meer G, De Kroon AI. (2011). Lipid map of the mammalian cell. J Cell Sci 124:5–8
- Wymann MP, Schneiter R. (2008). Lipid signalling in disease. Nat Rev Mol Cell Biol 9:162–76
- Yang WL, Bai Q, Li DD, et al. (2013). Changes of urinary phospholipids in the chronic kidney disease patients. Biomarkers 18:601–6
- Zhu C, Liang QL, Hu P, et al. (2011). Phospholipidomic identification of potential plasma biomarkers associated with type 2 diabetes mellitus and diabetic nephropathy. Talanta 85:1711–20